Treatment-Resistant Depression: New Therapies on the Horizon

References

• Wells KB. Stewart A. Hays RD, Burnam MA, Rogers W, Daniels M, Berry S. Greenfield S. Ware 1: The functioning and well-being of depressed patients: Results from the Medi-cal Outcomes Study. LAMA 1989; 262:914–919
   Google Scholar
• Hirschfeld RNI, Russell JM: Assessment and treatment of sui-cidal patients. N Engl. Med 1997; 337:910–915
   PubMed Web of Science ®Google Scholar
• Agency for Health Care Policy and Research. Depression in primary care: Guideline overview. J Natl Med Assoc 1993; 85(7):501–503
   Google Scholar
• Nierenberg AA. White K: What next? A review of phar-macologic strategies for treatment resistant depression. Psy-chopharrn Bull 1990; 26:429–460
   PubMedGoogle Scholar
• Thase ME, Kupfer DJ: Characteristics of treatment-resistant depression. In: Zohar J. Belmaker RH. eds. Treating Re-sistant Depression: II. New York: PN1A Publishing; 1987: 23–45
   Google Scholar
• Fava M. Davidson KG: Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19:179–200
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ: When at first you don't succeed: Sequen-tial strategies for antidepressant responders. J Clin Psychiatry 1997; 58\(Suppl. 13):23–29
   Google Scholar
• Rush Al, Trivedi MH: Treating depression to remission. Psy-chiatr Ann 1995; 25:704–709
   Web of Science ®Google Scholar
• Thase ME, Rush AJ: Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995:1081–1097
   Google Scholar
• Thase ME, Howland RH, Friedman ES: Treating antide-pressant nonresponders with augmentation strategies: An overview. J Clin Psychiatry 1998; 59\(Suppl. 5):5–12
   Google Scholar
• Trivedi MH, Kleiber BA: Using treatment algorithms for the effective management of treatment-resistant depression. J Clin Psychiatry 2001; 62\(Supp1)18: 25–29.
   Google Scholar
• Trivedi MH, Rush AJ, Pan JY, Carmody TJ: Which depressed patients respond to nefazodone and when? J Clin Psychiatry 2001; 62(3):158–163
   Google Scholar
• Enns MW, Swenson JR, McIntyre RS, Swinson RP, Kennedy SH: CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders, VII: comorbidity. Can J Psychiatry 2001; 46\(Suppl. 1):77S–90S
   Google Scholar
• Franco-Bronson K: The management of treatment-resistant depression in the medically ill. Psychiatr Clin North Am 1996; 19(2):329–350
   PubMed Web of Science ®Google Scholar
• Cadieux RI: Practical management of treatment-resistant de-pression. Am Fam Physician 1998; 58:2059–2062
   PubMedGoogle Scholar
• Keller MB, Lavori PW, Mueller TI, Endicott I, Coryell W, Hirschfeld RM, Shea T: Time to recovery, chronicity and levels of psychopathology in major depression: A five-year prospec-tive follow-up of 431 subjects. Major depressive disorder. Arch Gen Psychiatry 1992; 49:809–816
   PubMed Web of Science ®Google Scholar
• Frank E, Kupfer DJ, Perel JM, Comes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093–1099
   PubMed Web of Science ®Google Scholar
• Byrne SE, Rothschild AJ: Loss of antidepressant efficacy dur-ing maintenance therapy: Possible mechanisms and treatment. J Clin Psychiatry 1998; 59:279–288
   PubMed Web of Science ®Google Scholar
• Zajecka JNI: Clinical issues in long-term treatment with an-tidepressants. J Clin Psychiatry 2000; 61\(Suppl. 2):20–25
   Google Scholar
• Nelson JC: Overcoming treatment resistance in depression. Clin Psychiatry 1998; 59\(Suppl. 16):13–19
   Google Scholar
• Fava M: Management of nonresponse and intolerance: Switch-ing strategies. J Clin Psychiatry 2000: 61\(Suppl. 2):10–12
   Google Scholar
• Brown W, Harrison W: Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull 1992; 28:253–256
   PubMed Web of Science ®Google Scholar
• Brown WA, Harrison W: Are patients who are intolerant to one serotonin selective re uptake inhibitor intolerant to an-other? J Clin Psychiatry 1095; 56(1):30–34
   Google Scholar
• Joffe RT, Levitt AJ, Sokolov ST, Young LT: Response to an open trial of a second SSRI in major depression. J Clin Psy-chiatry 1996; 57:114–115
   Google Scholar
• Thase ME, Blomgren SL, Birkett MA, Apter IT, Tepner RG: Fluoxetine treatment of patients with major depressive disor-der who failed initial treatment with sertraline. J Clin Psychi-atry 1997; 58(1):16–21
   Web of Science ®Google Scholar
• Nurnberg FIG, Thompson PM, Hensley PL: Antidepressant medication change in a clinical treatment setting: A compar-ison of the effectiveness of selective serotonin reuptake in-hibitors. J Clin Psychiatry 1999; 60(9):574–579
   Google Scholar
• Fred man Si. Fava M. Kienke AS: Partial response. non-response. and relapse with selective serotonin reuptake in-hibitors in major depression: A survey of current "next-step" practices. J Clin Psychiatry 2000; 61: 403–408
   Google Scholar
• Thase ME, Rush Al. Howland RH, Kornstein SG, Kocsis IH, Gelenberg AJ, Schatzberg AF, Koran LM, Keller MB. Russell JM, Hirschfeld RM, LaVange LM, Klein DN, Fawcett J. Harrison W: Double-blind switch study of imipramine or ser-traline treatment of antidepressant-resistant chronic depres-sion. Arch Gen Psychiatry 2002; 59(3):233–239
   Google Scholar
• Thase ME, Friedman ES, Howland RH: Venlafaxine and treatment-resistant depression. Depress Anxiety 2000; 12\(Suppl. 1):55–62
   Google Scholar
• Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M: Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment fail-ure: An open-label trial. J Clin Psychiatry 2001; 62(6):413–420
   PubMedGoogle Scholar
• Nelson JC: Augmentation strategies in depression 2000. J Clin Psychiatry 2000; 61\(Suppl. 2):13–19
   Google Scholar
• Rush AJ, Prien RF: From scientific knowledge to the clini-cal practice of psychopharmacology: can the gap be bridged? Psychopharmacol Bull 1995; 31(1):7–20
   Google Scholar
• Zajecka J, Tracy KA, Mitchell S: Discontinuation symp-toms after treatment with serotonin reuptake inhibitors: A literature review. J Clin Psychiatry 1997; 58(7):291–297
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT: Efficacy of the combination of fluoxethie and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993; 54:338–342
   PubMed Web of Science ®Google Scholar
• Wolfersdorf M, Konig F, Straub R: Pharmacotherapy of delu-sional depression: Experience with combination of antidepres-sants with zotepine and haloperidol as neuroleptics. Neuropsy-chobiology 1994; 29:189–193
   Google Scholar
• Tran PV, Dellva MA, Tollefson GD, Beasley CM, Jr, Potvin JH, Kiesler GM: Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58:205–211
   Web of Science ®Google Scholar
• Tollefson GD, Beasley CM, Jr, Tamura RN, Tran PV, Potvin JH: Blind, controlled, long-term study of the com-parative incidence of treatment-emergent tardive dyskinesia with olanzapine or haldol. Am J Psychiatry 1997; 154:1248–1254
   PubMed Web of Science ®Google Scholar
• Borison RL, Pathiraja AP, Diamond BI, Meibach RC: Risperi-done: Clinical safety and efficacy in schizophrenia. Psy-chopharmacol Bull 1992; 28:213–218
   PubMed Web of Science ®Google Scholar
• Lukoski JM, Aghajanian GK: Effects of ketanserin on neu-ronal responses to serotonin in the prefrontal cortex, lat-eral geniculate, and dorsal raphe nucleus. Neuropharmacology 1985; 24:265–273
   Google Scholar
• Ostroff R, Nelson JC: Risperidone augmentation of SSRIs in major depression. J Clin Psychiatry 1999; 50:256–259
   Google Scholar
• Zhang W, Bymaster FP: The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antago-nism of dopamine DI, D2, D3,5HT2A and muscarinic recep-tors. Psychopharmacology 1999; 141:267–278
   PubMedGoogle Scholar
• Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P. Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharma-cology 1996; 14:87–96
   Google Scholar
• Tollefson GD, Sanger TM, Lu Y, Thieme ME: Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250–258
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M. Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 58:131–134
   Google Scholar
• Zhang W. Perry KW, Wong DT, Potts BD, Bao J. Tollefson GD. Bymaster FP: Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on nore-pinephrine and dopamine release in rat prefrontal cortex. Neu-ropsychopharmacology 2000; 23:250–262
   Google Scholar
• Harro J. Oreland L: Depression as a spreading adjustment dis-order of monoaminergic neurons: A case for primary impli-cation of the locus coeruleus. Brain Res Brain Res Rev 2001; 38(1/2):79–128
   Google Scholar
• Pacher P, Kohegyi E, Kecskemeti V, Furst S: Current trends in the development of new antidepressants. Curr Med Chem 2001; 8(2):89–100
   PubMedGoogle Scholar
• Lesch K P: Mouse anxiety: The power of knockout. Pharma-cogenomics J 2001; 1(3):187–192
   Google Scholar
• Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, Poncelet M, Gueudet C, Desvignes C, Le Fur G, Soubrie P: Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticorropin-releasing factor function. J Pharmacol Exp Titer 2001; 299(2):449–458
   Web of Science ®Google Scholar
• Haddjeri N, Blier P: Sustained blockade of neurokinin-1 re-ceptors enhances serotonin neurotransmission. Biol Psychia-try 2001; 50(3):191–199
   Google Scholar
• Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, Henry TR, Collins SD, Vaughn By, Gilmartin RC, Labar DR, Morris GL 3rd, Salinsky MC, Osorio I, Ristanovic RK, Labiner DM, Jones JC, Murphy JV, Ney GC, Wheless JW: Vagus nerve stimulation therapy for partial-onset seizures. Neurology 1998; 51:48–55
   PubMed Web of Science ®Google Scholar
• The Vagus Nerve Study Group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology 1995; 45:224–30
   Google Scholar
• George MS, Sackeim HA, Rush AJ, Marangell LB, Nahas Z, Husain MM, Lisanby S, Burt T, Goldman J, Ballenger JC: Va-gus nerve stimulation: A new tool for brain research and ther-apy. Biol Psychiatry 2000; 47:287–295
   PubMed Web of Science ®Google Scholar
• Rush AJ, George MS, Sackeim HA: Vagus nerve stimula-tion (VNS) for treatment-resistant depressions: A multicenter study. Biol Psychiatry 2000; 47:276–286
   PubMed Web of Science ®Google Scholar
• Rosenbaum IF, Heninger G: Vagus nerve stimulation for treatment-resistant depression. Biol Psychiatry 2000; 47:273–275. Editorial.
   Google Scholar
• Wassermann EM, Lisanby SH: Therapeutic application of repetitive transcranial magnetic stimulation: A review. Clin Neurophysiology 2001; 112:1367–1377
   PubMed Web of Science ®Google Scholar
• Padberg F, Zwanzger P. Thoma H, Kathmann N, Haag C. Greenberg BD, Hampel H, Moller HJ: Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: Comparative study of fast, slow, and sham rTMS. Psychiatr Res 1999; 88:163–171
   Google Scholar
• Loo C, Mitchell P, Sachdev P. McDarrnont B, Parker G, Gandevia S: Double-blind controlled investigation of transcra-nial magnetic stimulation for the treatment of resistant major depression. Am J Psychiatry 1999; 156:946–948
   Google Scholar
• Berman RM,Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, Charney DS, Boutros NN: A randomized clini-cal trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry 2000; 47:332–337
   PubMed Web of Science ®Google Scholar
• Lisanby SH, Luber B, Finck AD, Schroeder C, Sackeim HA: Deliberate seizure induction with repetitive transcranial mag-netic stimulation. Arch Gen Psychiatry 2001; 58:199–200. Er-ratum in: Arch Gen Psychiatry 2001; 58:515
   PubMed Web of Science ®Google Scholar
• Lisanby SH, Schlaepfer TE, Fisch HU, Sackeim HA: Magnetic seizure induction for the .treatment of major depression [let-ter]. Arch Gen Psychiatry 2001; 58:303–305
   PubMed Web of Science ®Google Scholar
• Lisanby SH, Luber B, Barroilhet L, Neufeld E, Schlaepfer T Sackeim HA: Magnetic seizure therapy (MST): Acute cogni-tive effects of MST compared with ECT. J ED' 2001; 17:77. Abstract 4
   Google Scholar
• Crismon ML, Trivedi M, Pigott TA, Rush Al, Hirschfeld RM, Kahn DA, DeBattista C, Nelson JC, Nierenberg AA, Sackeim HA, 'Thase ME: The Texas Medication Algorithm Project: Re-port of the Texas Consensus Conference Panel on medication treatment of major depressive disorder. J Clin Psychiatry 1999; 60:142–156
   PubMed Web of Science ®Google Scholar